Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Sleep Med ; 107: 137-148, 2023 07.
Article in English | MEDLINE | ID: mdl-37178545

ABSTRACT

BACKGROUND: The acute effect during positive pressure titration and long term efficacy of acetazolamide (AZT) in high loop gain sleep apnea (HLGSA) is inadequately assessed. We predicted that AZT may improve HLGSA in both conditions. METHODS: A retrospective analysis of polysomnograms from patients with presumed HLGSA and residual respiratory instability administered AZT (125 or 250 mg) about 3 h into an initially drug-free positive pressure titration. A responder was defined as ≥ 50% reduction of the apnea hypopnea index(AHI 3% or arousal) before and after AZT. A multivariable logistic regression model estimated responder predictors. Long term efficacy of AZT was assessed by comparing both auto-machine (aREIFLOW) and manually scored respiratory events (sREIFLOW) extracted from the ventilator, prior to and after 3 months of AZT, in a subset. RESULTS: Of the 231 participants (median age of 61[51-68] years) and 184 (80%) males in the acute effect testing: 77 and 154 patients were given 125 mg and 250 mg AZT. Compared to PAP alone, PAP plus AZT was associated with a lower breathing related arousal index (8 [3-16] vs. 5 [2-10], p < 0.001), and AHI3% (19 [7-37] vs. 11 [5-21], p < 0.001); 98 patients were responders. The non-rapid eye movement sleep (NREM) AHI3% (OR 1.031, 95%CI [1.016-1.046], p < 0.001) was a strong predictor for responder status with AZT exposure. In the 109 participants with 3-month data, both aREIFLOW and sREIFLOWwere significantly reduced after AZT. CONCLUSIONS: AZT acutely and chronically reduced residual sleep apnea in presumed HLGSA; NREM AHI3% is a response predictor. AZT was well tolerated and beneficial for at least 3 months.


Subject(s)
Sleep Apnea Syndromes , Sleep Apnea, Obstructive , Male , Humans , Middle Aged , Aged , Female , Acetazolamide/pharmacology , Acetazolamide/therapeutic use , Sleep Apnea, Obstructive/drug therapy , Retrospective Studies , Sleep Apnea Syndromes/drug therapy , Respiration , Continuous Positive Airway Pressure
2.
J Am Assoc Nurse Pract ; 25(12): 641-3, 2013 Dec.
Article in English | MEDLINE | ID: mdl-24170417

ABSTRACT

PURPOSE: To bring attention to a rare diagnosis in the pediatric population that is in the differential diagnosis for not well-controlled asthma. DATA SOURCES: Case presentation. CONCLUSIONS: Pulmonary carcinoid tumors are rare and usually present late in adolescence. Most of these tumors are located in the proximal airways and symptoms may be similar to those of asthma including cough, wheeze, chest pain, or recurrent pneumonia. IMPLICATIONS FOR PRACTICE: Bronchial carcinoid should be in the differential diagnosis for adolescents with difficult to control asthma, who have symptoms including chronic cough and focal wheeze. Referral to a pulmonary specialist should be considered to help work up the differential diagnoses.


Subject(s)
Bronchial Neoplasms/complications , Bronchial Neoplasms/diagnosis , Carcinoid Tumor/complications , Carcinoid Tumor/diagnosis , Respiratory Sounds/etiology , Adolescent , Bronchial Neoplasms/therapy , Carcinoid Tumor/therapy , Female , Humans
SELECTION OF CITATIONS
SEARCH DETAIL
...